Skip to main content

Risk for Rapid Progression Explored in Patients With CKD Stage G3

Medically reviewed by Carmen Pope, BPharm. Last updated on March 13, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, March 13, 2024 -- Individuals with incident chronic kidney disease (CKD) stage G3 have a 14.6 percent three-year risk for rapid progression, according to a study recently published in Nephrology Dialysis Transplantation.

Anne H.S. Vestergaard, M.D., Ph.D., from Aarhus University in Denmark, and colleagues conducted a nationwide, population-based cohort study to examine the risk for rapid progression, kidney failure, hospitalization, and death among adults with incident CKD stage G3 in 2017 to 2020. Risk markers were examined by constructing a heat map showing the risk for rapid progression based on predefined markers.

The researchers found that the three-year risk for rapid progression was 14.6 percent among 133,443 individuals with incident CKD stage G3. The three-year risks were 0.3, 53.3, and 18.1 percent for kidney failure, hospitalization, and death, respectively. The three-year risk for rapid progression in the heat map varied from 7 percent in women without albuminuria, hypertension/cardiovascular disease, or diabetes to 46 to 47 percent in men and women with severe albuminuria, diabetes, and hypertension/cardiovascular disease.

"The present population-based study highlights the potential for using readily available markers in routine clinical care to identify individuals at particularly high risk of rapid progression of CKD who may benefit from regular monitoring and prophylactic interventions to slow further decline in kidney function and associated adverse events," the authors write.

Several authors disclosed ties to AstraZeneca, which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease

TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...

Women Face Worse Chronic Kidney Disease Management in Primary Care

MONDAY, May 20, 2024 -- Women receive worse primary care-based chronic kidney disease (CKD) management than men, according to a research letter published online May 16 in the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.